Accepted Manuscript



Title: Mechanisms of epileptogenesis and preclinical approach to antiepileptogenic therapies

Authors: Krzysztof Łukawski, Marta Andres-Mach, Mirosław Czuczwar, Jarogniew J. Łuszczki, Krzysztof Kruszyński, Stanisław J. Czuczwar

 PII:
 S1734-1140(17)30195-0

 DOI:
 http://dx.doi.org/doi:10.1016/j.pharep.2017.07.012

 Reference:
 PHAREP 765

To appear in:

Received date:	10-3-2017
Revised date:	17-5-2017
Accepted date:	12-7-2017

Please cite this article as: Krzysztof Łukawski, Marta Andres-Mach, Mirosław Czuczwar, Jarogniew J.Łuszczki, Krzysztof Kruszyński, Stanisław J.Czuczwar, Mechanisms of epileptogenesis and preclinical approach to antiepileptogenic therapies (2010), http://dx.doi.org/10.1016/j.pharep.2017.07.012

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

ACCEPTED MANUSCRIPT

Mechanisms of epileptogenesis and preclinical approach to antiepileptogenic therapies Short title: Epileptogenesis and antiepileptogenic therapies

Krzysztof Łukawski^{a,b}, Marta Andres-Mach^c, Mirosław Czuczwar^d, Jarogniew J. Łuszczki^{b,c}, Krzysztof Kruszyński^a, Stanisław J. Czuczwar^{a,b,*}

^aDepartment of Physiopathology, Institute of Rural Health, Lublin, Poland ^bDepartment of Pathophysiology, Medical University of Lublin, Lublin, Poland ^cIsobolographic Analysis Laboratory, Institute of Rural Health, Lublin, Poland ^d2nd Department of Anesthesiology and Intensive Care, Medical University of Lublin, Lublin, Poland

*Corresponding author. *E-mail address:* czuczwarsj@yahoo.com

Abstract

The prevalence of epilepsy is estimated 5-10 per 1000 population and around 70% of patients with epilepsy can be sufficiently controlled by antiepileptic drugs (AEDs). Epileptogenesis is the process responsible for converting normal into an epileptic brain and mechanisms responsible include among others: inflammation, neurodegeneration, neurogenesis, neural reorganization and plasticity. Some AEDs may be antiepileptiogenic (diazepam, eslicarbazepine) but the correlation between neuroprotection and inhibition of epileptogenesis is not evident. Antiepileptogenic activity has been postulated for mTOR ligands, resveratrol and losartan. So far, clinical evidence gives some hope for levetiracetam as an AED inhibiting epileptogenesis in neurosurgical patients. Biomarkers for epileptogenesis are needed for the proper selection of patients for evaluation of potential antiepileptogenic compounds.

Keywords: Epilepsy, Epileptogenesis, Antiepileptic drugs, Antiepileptogenic compounds, Traumatic brain injury

Introduction

It is thought that epilepsy with 65 million people affected worldwide is the most common, chronic, serious neurological disease [1]. The prevalence of epilepsy is 5-10 per

Download English Version:

https://daneshyari.com/en/article/8349653

Download Persian Version:

https://daneshyari.com/article/8349653

Daneshyari.com